FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154133150> ?p ?o ?g. }

• W3154133150 endingPage "171" @default.
• W3154133150 startingPage "161" @default.
• W3154133150 abstract "Introduction: Dacomitinib is a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Recent results from ARCHER 1050, the first randomized, open-label, Phase 3 trial of a second-generation vs. a first-generation EGFR TKI, showed that dacomitinib improves progression-free survival and overall survival compared with gefitinib as a first-line treatment in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).Areas covered: We review the efficacy and safety of dacomitinib as a first-line treatment of EGFR mutation-positive NSCLC, including the management of toxicity, and evaluate the activity of dacomitinib against brain metastases. Additionally, the optimal treatment sequence given EGFR TKI choice, resistance mechanisms, activity against rare mutations, and real-world dosing is discussed.Expert opinion: The introduction of EGFR TKIs has changed the treatment strategy for patients with EGFR mutation-positive NSCLC. The second- and third-generation EGFR TKIs are the result of research elucidating mechanisms of resistance to first-generation EGFR TKIs. There is now more than one treatment option for patients with EGFR mutation-positive advanced NSCLC that improves survival, highlighting the need to more clearly understand the use of the right drug for the right person at the right time and how the appropriate treatment sequence may provide optimal outcomes for these patients." @default.
• W3154133150 created "2021-04-26" @default.
• W3154133150 creator A5003412464 @default.
• W3154133150 creator A5066717752 @default.
• W3154133150 creator A5086739009 @default.
• W3154133150 creator A5087211784 @default.
• W3154133150 date "2021-04-13" @default.
• W3154133150 modified "2023-10-16" @default.
• W3154133150 title "Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer" @default.
• W3154133150 cites W1514134885 @default.
• W3154133150 cites W1514301740 @default.
• W3154133150 cites W1887041282 @default.
• W3154133150 cites W1938603543 @default.
• W3154133150 cites W1980497534 @default.
• W3154133150 cites W1984004254 @default.
• W3154133150 cites W2007528734 @default.
• W3154133150 cites W2043696829 @default.
• W3154133150 cites W2055102246 @default.
• W3154133150 cites W2063391304 @default.
• W3154133150 cites W2088540000 @default.
• W3154133150 cites W2096198395 @default.
• W3154133150 cites W2097781997 @default.
• W3154133150 cites W2107775354 @default.
• W3154133150 cites W2110841878 @default.
• W3154133150 cites W2111662961 @default.
• W3154133150 cites W2112098753 @default.
• W3154133150 cites W2113508099 @default.
• W3154133150 cites W2123753884 @default.
• W3154133150 cites W2129360604 @default.
• W3154133150 cites W2132157071 @default.
• W3154133150 cites W2133149289 @default.
• W3154133150 cites W2135192471 @default.
• W3154133150 cites W2137005514 @default.
• W3154133150 cites W2138851777 @default.
• W3154133150 cites W2139236349 @default.
• W3154133150 cites W2143913849 @default.
• W3154133150 cites W2149654081 @default.
• W3154133150 cites W2149733252 @default.
• W3154133150 cites W2159192794 @default.
• W3154133150 cites W2160982674 @default.
• W3154133150 cites W2161152839 @default.
• W3154133150 cites W2161821474 @default.
• W3154133150 cites W2166084034 @default.
• W3154133150 cites W2171139285 @default.
• W3154133150 cites W2210071992 @default.
• W3154133150 cites W2339311613 @default.
• W3154133150 cites W2466033276 @default.
• W3154133150 cites W2507541911 @default.
• W3154133150 cites W2512922897 @default.
• W3154133150 cites W2558415788 @default.
• W3154133150 cites W2587420003 @default.
• W3154133150 cites W2608495247 @default.
• W3154133150 cites W2621385743 @default.
• W3154133150 cites W2744886365 @default.
• W3154133150 cites W2760639821 @default.
• W3154133150 cites W2767275374 @default.
• W3154133150 cites W2770828094 @default.
• W3154133150 cites W2785626971 @default.
• W3154133150 cites W2790649727 @default.
• W3154133150 cites W2806325305 @default.
• W3154133150 cites W2889646458 @default.
• W3154133150 cites W2898171786 @default.
• W3154133150 cites W2914671825 @default.
• W3154133150 cites W2915087191 @default.
• W3154133150 cites W2921027277 @default.
• W3154133150 cites W2960762304 @default.
• W3154133150 cites W2962479261 @default.
• W3154133150 cites W2967398721 @default.
• W3154133150 cites W2975758168 @default.
• W3154133150 cites W2979140055 @default.
• W3154133150 cites W2981797636 @default.
• W3154133150 cites W2987053327 @default.
• W3154133150 cites W2990041408 @default.
• W3154133150 cites W2991243934 @default.
• W3154133150 cites W2999801017 @default.
• W3154133150 cites W3016460488 @default.
• W3154133150 cites W3082062836 @default.
• W3154133150 cites W3111257261 @default.
• W3154133150 doi "https://doi.org/10.1080/23808993.2021.1909420" @default.
• W3154133150 hasPublicationYear "2021" @default.
• W3154133150 type Work @default.
• W3154133150 sameAs 3154133150 @default.
• W3154133150 citedByCount "4" @default.
• W3154133150 countsByYear W31541331502022 @default.
• W3154133150 countsByYear W31541331502023 @default.
• W3154133150 crossrefType "journal-article" @default.
• W3154133150 hasAuthorship W3154133150A5003412464 @default.
• W3154133150 hasAuthorship W3154133150A5066717752 @default.
• W3154133150 hasAuthorship W3154133150A5086739009 @default.
• W3154133150 hasAuthorship W3154133150A5087211784 @default.
• W3154133150 hasBestOaLocation W31541331501 @default.
• W3154133150 hasConcept C121608353 @default.
• W3154133150 hasConcept C126322002 @default.
• W3154133150 hasConcept C143998085 @default.
• W3154133150 hasConcept C2776256026 @default.
• W3154133150 hasConcept C2777506169 @default.
• W3154133150 hasConcept C2778087573 @default.
• W3154133150 hasConcept C2778820342 @default.

• next